Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.

Kai L, Wang Z, Yao W, Dong K, Xiao X.

J Cancer Res Clin Oncol. 2014 Mar;140(3):471-6. doi: 10.1007/s00432-013-1549-3. Epub 2014 Jan 25.

PMID:
24464150
2.

Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.

Ji Y, Chen S, Xiang B, Li K, Xu Z, Yao W, Lu G, Liu X, Xia C, Wang Q, Li Y, Wang C, Yang K, Yang G, Tang X, Xu T, Wu H.

Int J Cancer. 2017 Aug 15;141(4):848-855. doi: 10.1002/ijc.30775. Epub 2017 May 26.

PMID:
28486787
3.

Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up.

Wang Z, Li K, Yao W, Dong K, Xiao X, Zheng S.

Pediatr Blood Cancer. 2015 Apr;62(4):577-80. doi: 10.1002/pbc.25296. Epub 2014 Oct 24.

PMID:
25346262
4.

Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms.

Iacobas I, Simon ML, Amir T, Gribbin CE, McPartland TG, Kaufman MR, Calderwood S, Nosher JL.

Clin Imaging. 2015 May-Jun;39(3):529-32. doi: 10.1016/j.clinimag.2015.01.003. Epub 2015 Jan 14.

PMID:
25662209
5.

Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma.

Oza VS, Mamlouk MD, Hess CP, Mathes EF, Frieden IJ.

Pediatr Dermatol. 2016 Mar-Apr;33(2):e88-92. doi: 10.1111/pde.12787. Epub 2016 Feb 11.

PMID:
26864138
6.

Successful treatment of Kaposiform hemangioendothelioma with everolimus.

Uno T, Ito S, Nakazawa A, Miyazaki O, Mori T, Terashima K.

Pediatr Blood Cancer. 2015 Mar;62(3):536-8. doi: 10.1002/pbc.25241. Epub 2014 Oct 12.

PMID:
25306933
7.

Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus.

Jahnel J, Lackner H, Reiterer F, Urlesberger B, Urban C.

Klin Padiatr. 2012 Oct;224(6):395-7. doi: 10.1055/s-0032-1323823. Epub 2012 Oct 15. No abstract available.

PMID:
23070861
8.

Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.

Matsumoto H, Ozeki M, Hori T, Kanda K, Kawamoto N, Nagano A, Azuma E, Miyazaki T, Fukao T.

J Pediatr Hematol Oncol. 2016 Nov;38(8):e322-e325.

PMID:
26907642
9.

Successful treatment of kaposiform lymphangiomatosis with sirolimus.

Wang Z, Li K, Yao W, Dong K, Xiao X, Zheng S.

Pediatr Blood Cancer. 2015 Jul;62(7):1291-3. doi: 10.1002/pbc.25422. Epub 2015 Jan 18.

PMID:
25598153
10.

Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with embolization and vincristine in two newborns.

Garcia-Monaco R, Giachetti A, Peralta O, Napoli N, Lobos P, Gioseffi L, Mariani G.

J Vasc Interv Radiol. 2012 Mar;23(3):417-22. doi: 10.1016/j.jvir.2011.12.007.

PMID:
22365299
11.

Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.

Chiu YE, Drolet BA, Blei F, Carcao M, Fangusaro J, Kelly ME, Krol A, Lofgren S, Mancini AJ, Metry DW, Recht M, Silverman RA, Tom WL, Pope E.

Pediatr Blood Cancer. 2012 Nov;59(5):934-8. doi: 10.1002/pbc.24103. Epub 2012 Feb 2.

12.

Rapidly enlarging "bruise" on the back of an infant. Kaposiform hemangioendothelioma complicated by Kasabach-Merritt syndrome.

Chan S, Cassarino DS.

JAMA Dermatol. 2013 Nov;149(11):1337-8. doi: 10.1001/jamadermatol.2013.519. No abstract available.

PMID:
24005816
13.

Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus.

Wang Z, Li K, Dong K, Xiao X, Zheng S.

J Pediatr Hematol Oncol. 2015 Jan;37(1):72-3. doi: 10.1097/MPH.0000000000000068. No abstract available.

PMID:
24309604
14.

Laryngomalacia and complicated, life-threatening mTOR-positive Kaposiform hemangioendothelioma cured by Supraglottoplasty and sirolimus.

Schroeder U, Lauten M, Stichtenoth G, Gebhard MP, Buchholz M, Kaiser MM.

Klin Padiatr. 2014 Nov;226(6-7):362-8. doi: 10.1055/s-0034-1372587. Epub 2014 May 8.

PMID:
24810750
15.

Sirolimus in the Treatment of Vascular Anomalies.

Triana P, Dore M, Cerezo VN, Cervantes M, Sánchez AV, Ferrero MM, González MD, Lopez-Gutierrez JC.

Eur J Pediatr Surg. 2017 Feb;27(1):86-90. doi: 10.1055/s-0036-1593383. Epub 2016 Oct 10.

PMID:
27723921
16.

Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals.

Croteau SE, Liang MG, Kozakewich HP, Alomari AI, Fishman SJ, Mulliken JB, Trenor CC 3rd.

J Pediatr. 2013 Jan;162(1):142-7. doi: 10.1016/j.jpeds.2012.06.044. Epub 2012 Aug 4.

17.

Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with vincristine and ticlopidine.

Barabash-Neila R, García-Rodríguez E, Bernabeu-Wittel J, Bueno-Rodríguez I, Ramírez-Villar G, López-Gutierrez JC.

Indian J Pediatr. 2012 Oct;79(10):1386-7. doi: 10.1007/s12098-011-0625-4. Epub 2011 Dec 10. No abstract available.

PMID:
22161581
18.

Treatment of childhood kaposiform hemangioendothelioma with sirolimus.

Blatt J, Stavas J, Moats-Staats B, Woosley J, Morrell DS.

Pediatr Blood Cancer. 2010 Dec 15;55(7):1396-8. doi: 10.1002/pbc.22766.

PMID:
20730884
19.

Imaging findings of Kaposiform Hemangioendothelioma in children.

Ryu YJ, Choi YH, Cheon JE, Kim WS, Kim IO, Park JE, Kim YJ.

Eur J Radiol. 2017 Jan;86:198-205. doi: 10.1016/j.ejrad.2016.11.015. Epub 2016 Nov 10.

PMID:
28027747
20.

Treatment of kaposiform hemangioendothelioma and tufted angioma.

Liu XH, Li JY, Qu XH, Yan WL, Zhang L, Yang C, Zheng JW.

Int J Cancer. 2016 Oct 1;139(7):1658-66. doi: 10.1002/ijc.30216. Epub 2016 Jun 28. Review.

Supplemental Content

Support Center